fda approval tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy FDA approves weight-loss drug Zepbound

doi: 10.1016/j.phymed.2024.156122 170 HeYZhuYShuiXHuangZLiKLeiW

however, a concern has been raised because harmful consequences of using it have been reported

They also might be prescribed lower dosages in clinical practice than were used in the drug trials.Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide.Average body weight loss after a year was nearly 9% for the whole group, results show.But weight loss varied based on when a person stopped taking the drugs, researchers found.Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says

Large meals overwhelm a slower-moving digestive system